These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 30799274)

  • 21. Frequency of the LRRK2 G2019S mutation in Italian patients affected by Parkinson's disease.
    Squillaro T; Cambi F; Ciacci G; Rossi S; Ulivelli M; Malandrini A; Mencarelli MA; Mari F; Renieri A; Ariani F
    J Hum Genet; 2007; 52(3):201-204. PubMed ID: 17235449
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CRISPR/Cas9 and piggyBac-mediated footprint-free LRRK2-G2019S knock-in reveals neuronal complexity phenotypes and α-Synuclein modulation in dopaminergic neurons.
    Qing X; Walter J; Jarazo J; Arias-Fuenzalida J; Hillje AL; Schwamborn JC
    Stem Cell Res; 2017 Oct; 24():44-50. PubMed ID: 28826027
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Using Extracellular miRNA Signatures to Identify Patients with LRRK2-Related Parkinson's Disease.
    Braunger LJ; Knab F; Gasser T
    J Parkinsons Dis; 2024; 14(5):977-991. PubMed ID: 38848197
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A common leucine-rich repeat kinase 2 gene mutation in familial and sporadic Parkinson's disease in Russia.
    Illarioshkin SN; Shadrina MI; Slominsky PA; Bespalova EV; Zagorovskaya TB; Bagyeva GKh; Markova ED; Limborska SA; Ivanova-Smolenskaya IA
    Eur J Neurol; 2007 Apr; 14(4):413-7. PubMed ID: 17388990
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structural Insights and Development of LRRK2 Inhibitors for Parkinson's Disease in the Last Decade.
    Thakur G; Kumar V; Lee KW; Won C
    Genes (Basel); 2022 Aug; 13(8):. PubMed ID: 36011337
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. RNA sequencing reveals MMP2 and TGFB1 downregulation in LRRK2 G2019S Parkinson's iPSC-derived astrocytes.
    Booth HDE; Wessely F; Connor-Robson N; Rinaldi F; Vowles J; Browne C; Evetts SG; Hu MT; Cowley SA; Webber C; Wade-Martins R
    Neurobiol Dis; 2019 Sep; 129():56-66. PubMed ID: 31085228
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lrrk2 mutations in South America: A study of Chilean Parkinson's disease.
    Perez-Pastene C; Cobb SA; Díaz-Grez F; Hulihan MM; Miranda M; Venegas P; Godoy OT; Kachergus JM; Ross OA; Layson L; Farrer MJ; Segura-Aguilar J
    Neurosci Lett; 2007 Jul; 422(3):193-7. PubMed ID: 17614198
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative blood transcriptome analysis in idiopathic and LRRK2 G2019S-associated Parkinson's disease.
    Infante J; Prieto C; Sierra M; Sánchez-Juan P; González-Aramburu I; Sánchez-Quintana C; Berciano J; Combarros O; Sainz J
    Neurobiol Aging; 2016 Feb; 38():214.e1-214.e5. PubMed ID: 26675812
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective Role of PAK6 and 14-3-3γ as Biomarkers for Parkinson's Disease.
    Giusto E; Maistrello L; Iannotta L; Giusti V; Iovino L; Bandopadhyay R; Antonini A; Bubacco L; Barresi R; Plotegher N; Greggio E; Civiero L
    J Parkinsons Dis; 2024; 14(3):495-506. PubMed ID: 38640169
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Increased peripheral inflammation in asymptomatic leucine-rich repeat kinase 2 mutation carriers.
    Dzamko N; Rowe DB; Halliday GM
    Mov Disord; 2016 Jun; 31(6):889-97. PubMed ID: 26917005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Wild-type LRRK2 as a new potential therapeutic target in idiopathic Parkinson's disease.
    Sanjari Moghaddam H; Aarabi MH
    Mov Disord; 2018 Dec; 33(12):1876. PubMed ID: 30452792
    [No Abstract]   [Full Text] [Related]  

  • 33. Decreased Sirtuin Deacetylase Activity in LRRK2 G2019S iPSC-Derived Dopaminergic Neurons.
    Schwab AJ; Sison SL; Meade MR; Broniowska KA; Corbett JA; Ebert AD
    Stem Cell Reports; 2017 Dec; 9(6):1839-1852. PubMed ID: 29129681
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations.
    Alcalay RN; Levy OA; Waters CC; Fahn S; Ford B; Kuo SH; Mazzoni P; Pauciulo MW; Nichols WC; Gan-Or Z; Rouleau GA; Chung WK; Wolf P; Oliva P; Keutzer J; Marder K; Zhang X
    Brain; 2015 Sep; 138(Pt 9):2648-58. PubMed ID: 26117366
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Motor and non-motor features of Parkinson's disease in LRRK2 G2019S carriers versus matched controls.
    Gunzler SA; Riley DE; Chen SG; Tatsuoka CM; Johnson WM; Mieyal JJ; Walter EM; Whitney CM; Feng IJ; Owusu-Dapaah H; Mittal SO; Wilson-Delfosse AL
    J Neurol Sci; 2018 May; 388():203-207. PubMed ID: 29627023
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neural Stem Cells of Parkinson's Disease Patients Exhibit Aberrant Mitochondrial Morphology and Functionality.
    Walter J; Bolognin S; Antony PMA; Nickels SL; Poovathingal SK; Salamanca L; Magni S; Perfeito R; Hoel F; Qing X; Jarazo J; Arias-Fuenzalida J; Ignac T; Monzel AS; Gonzalez-Cano L; Pereira de Almeida L; Skupin A; Tronstad KJ; Schwamborn JC
    Stem Cell Reports; 2019 May; 12(5):878-889. PubMed ID: 30982740
    [TBL] [Abstract][Full Text] [Related]  

  • 37. LRRK2 in Parkinson's disease: genetic and clinical studies from patients.
    Kumari U; Tan EK
    FEBS J; 2009 Nov; 276(22):6455-63. PubMed ID: 19804413
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Olfactory deficits and cardiac 123I-MIBG in Parkinson's disease related to the LRRK2 R1441G and G2019S mutations.
    Ruiz-Martínez J; Gorostidi A; Goyenechea E; Alzualde A; Poza JJ; Rodríguez F; Bergareche A; Moreno F; López de Munain A; Martí Massó JF
    Mov Disord; 2011 Sep; 26(11):2026-31. PubMed ID: 21611983
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Motor and nonmotor heterogeneity of LRRK2-related and idiopathic Parkinson's disease.
    Marras C; Alcalay RN; Caspell-Garcia C; Coffey C; Chan P; Duda JE; Facheris MF; Fernández-Santiago R; Ruíz-Martínez J; Mestre T; Saunders-Pullman R; Pont-Sunyer C; Tolosa E; Waro B;
    Mov Disord; 2016 Aug; 31(8):1192-202. PubMed ID: 27091104
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generation of 2 induced pluripotent stem cell lines derived from patients with Parkinson's disease carrying LRRK2 G2385R variant.
    Cheng YC; Huang CY; Ho MC; Hsu YH; Syu SH; Lu HE; Lin HI; Lin CH; Hsieh PCH
    Stem Cell Res; 2018 Apr; 28():1-5. PubMed ID: 29414410
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.